E-Cigarettes and the Multiple Responsibilities of the FDA

Abstract

This paper considers the responsibilities of the FDA with regard to disseminating information about the benefits and harms of e-cigarettes. Tobacco harm reduction advocates claim that the FDA has been overcautious and has violated ethical obligations by failing to clearly communicate to the public that e-cigarettes are far less harmful than cigarettes. We argue, by contrast, that the FDA's obligations in this arena are more complex than they may appear at first blush. Though the FDA is accountable for informing the public about the health risks and benefits of products it regulates, it also has other roles (and attendant responsibilities) that inform when and how it should disseminate information. In addition to being a knowledge purveyor, it is also a knowledge producer, an advisor to the public, and a practical agent shaping the material conditions in which people make health-related choices. In our view, those other roles call for caution in the way the FDA interprets and communicates the available evidence.

Review of an up-to-date, emphatic, and concise perspective on e-cigarettes

“…In 2020, FDA implemented sales limitations within the United States; however, these policies were limited in scope, targeting specific flavours and items [38]. Due to the presence of heterogeneity, complexity, and limited transparency in relation to e-cigarette products, there exists a lack of comprehensive understanding regarding the exposures resulting from e-cigarette usage.…”